FDA
-
-
-
-
-
-
-
Rigel Announces Publication of Final 5-year Data on REZLIDHIA® (olutasidenib) in Patients with R/R mIDH1 AML in the Journal of Hematology & Oncology
-
-
-
-
-
-
-
Rigel Pharma (RIGL) announces seven upcoming poster presentations at 2025 ASCO
-
-
-
-
-
-
-
H.C. Wainwright Reiterates Buy Rating on Rigel Pharmaceuticals (RIGL)
-
-
-
-
-
-
-
Rigel Pharma (RIGL) Highlights Initial Data from Ongoing Phase 1b Study Evaluating R289 in LR-MDS at the 66th ASH Annual Meeting and Exposition
-
-
-
-
-
-
-
Rigel Pharmaceuticals Issues Dear Healthcare Provider Letter for GAVRETO® (pralsetinib)
-
-
-
-
-
-
-
Rigel Pharma (RIGL) and Optime Care Partner over GAVRETO Patients
-
-
-
-
-
-
-
Rigel Reports First Quarter 2024 Financial Results and Provides Business Update
-
312,667 total articles have been posted to this entity.
Click Here to Sign-Up for StreetInsider.com Premium to View All

